Full-Time

Quality Systems Senior Specialist

Global QMS

Orca Bio

Orca Bio

201-500 employees

Develops and commercializes safer cell therapies

Compensation Overview

$90k - $120k/yr

+ Pre-IPO equity + Annual bonus

Sacramento, CA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
ERP
ISO 9001
Quality Assurance (QA)
Data Analysis

Get referred to Orca Bio

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific or engineering discipline is required.
  • A minimum of 5+ years of relevant Quality Assurance or Quality Systems experience in a GxP-regulated environment is required, including at least 2-3 years in a leadership role.
  • Strong knowledge of global quality regulations and standards, including FDA, EMA, ICH, ISO 9001, 21 CFR Parts 210/211/820, and EU GMP, is required.
  • Proven experience leading Quality Management Review, internal audit programs, supplier management processes, and validation oversight is required.
  • Demonstrated success in establishing and trending quality performance metrics and key performance indicators is required.
  • Experience supporting or administering electronic Quality Management Systems and partnering with Information Technology for system enhancements is required.
  • The ability to organize, analyze, communicate, influence, and collaborate across functional and site boundaries is required.
Responsibilities
  • Plan, schedule, and execute internal audits across all sites and functions in accordance with the internal audit program.
  • Develop audit agendas, conduct interviews, review processes, and generate audit reports.
  • Support the global Quality Management Review process by ensuring timely data collection, analysis, and reporting to senior leadership.
  • Support the supplier qualification and management program, including risk assessments, supplier audits, and ongoing monitoring for GxP compliance.
  • Drive global inspection management activities and ensure cross-functional and site readiness for FDA, EMA, and other health authority inspections.
  • Provide oversight and guidance to site Quality Management Review administrators to ensure consistent quality system implementation across all sites.
  • Establish and monitor global Quality Management System key performance indicators, oversee quality-metric trending, and use data-driven insights to improve quality systems and performance.
  • Partner with Information Technology and business process owners to identify and implement Quality Management System enhancements, define requirements, drive prioritization, and ensure changes are validated and compliant.
  • Review, approve, and provide quality oversight for validation documentation, including equipment qualification, computer system validation, and process validation, for global enterprise systems such as MasterControl, enterprise resource planning systems, and TrackWise.
  • Collaborate with cross-functional and site leadership teams to drive continuous-improvement initiatives and ensure the Quality Management System evolves with business needs and regulatory expectations.
Desired Qualifications
  • An advanced degree is preferred.
  • Experience working in a multi-site or global quality organization is strongly preferred.

Orca Bio develops and commercializes cell therapies to improve outcomes for patients. It works by researching, developing, and producing therapies that use the body’s own cells to treat diseases, with products sold to healthcare providers who administer them to patients. The company aims to enhance the safety and effectiveness of cell therapies, making treatments more reliable for conditions that lack good options. Orca Bio differentiates itself through its focus on delivering safer, more effective therapies and by fostering a strong team culture with active stakeholder communication, including a regularly updated newsroom. Overall, its goal is to expand access to improved cell therapies and become a leading player in the cell therapy market.

Company Size

201-500

Company Stage

Series F

Total Funding

$542M

Headquarters

Menlo Park, California

Founded

2016

Get referred to Orca Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval on June 30, 2026 validates Orca Bio's platform and pipeline.
  • The company raised $250 million in December 2025, funding launch and expansion.
  • Princeton capacity and Sacramento hiring support commercialization and faster nationwide patient delivery.

What critics are saying

  • TREGZI costs $428,000, forcing transplant centers and payers into tough coverage fights.
  • Complex donor-specific manufacturing can bottleneck supply, delaying launches beyond the planned 25 centers.
  • Any post-marketing safety signal or FDA CMC issue would cripple Orca Bio's only commercial product.

What makes Orca Bio unique

  • Orca Bio's TREGZI won FDA approval on June 30, 2026, first precision cell therapy.
  • Its donor-derived regulatory T-cell design directly reduces chronic GVHD after transplant.
  • Princeton and Sacramento manufacturing create a bicoastal vein-to-vein network for personalized production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Associated Press
Jul 1st, 2026
FDA approves Tregzi, first donor immune cell therapy cutting serious transplant complications in blood cancer patients by 70%

The US Food and Drug Administration has approved Tregzi, the first regulatory T cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult blood cancer patients undergoing stem cell transplantation. The treatment uses donor-derived immune cells to help fight cancer whilst reducing the risk of chronic GVHD, a serious complication where transplanted donor cells attack the patient's body. In the PRECISION-T trial involving 187 patients, 78% of those receiving Tregzi achieved chronic GVHD-free survival at one year, compared to 38.4% receiving standard transplants. Only 12.6% of Tregzi patients developed serious chronic GVHD within one year versus 44% in the control group. The treatment, developed by Orca Biosystems, received Orphan Drug and Regenerative Medicine Advanced Therapy designations.

Fierce Pharma
Jul 1st, 2026
Orca Bio secures FDA approval for $428K cell therapy Tregzi, eyes potential IPO

Orca Bio has secured FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. The allogeneic regulatory T cell-based immunotherapy is approved as an alternative stem cell transplant to improve survival free of chronic graft-versus-host disease in adults with hematological malignancies. In the phase 3 Precision-T trial involving 187 patients, 78% who received Tregzi were alive and free from chronic GVHD at one year, compared to 38% with standard transplants—a 74% improvement. Overall survival was 94% versus 83%. Orca is pricing Tregzi at $428,000 wholesale acquisition cost. The company recently raised $250 million and is launching at select centres, aiming for 25 by year-end. CEO Nate Fernhoff said the company is "well capitalised" for launch but didn't rule out a future IPO.

Associated Press
Jun 30th, 2026
Orca Bio's TREGZI becomes first FDA-approved precision cell therapy for blood cancer transplants

Orca Bio has received US FDA approval for TREGZI, the first precision-engineered cell therapy for matched-donor hematopoietic stem cell transplantation in adults with hematological malignancies. The therapy uses donor cells to reconstitute the immune system whilst suppressing graft-versus-host disease (GVHD). The approval is based on the Phase 3 Precision-T study of 187 patients with acute myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic syndrome and mixed-phenotype acute leukaemia. Results showed 78% chronic GVHD-free survival at 12 months with TREGZI compared to 38% with conventional transplant. Overall survival was 94% versus 83%, whilst non-relapse mortality was 3% compared to 13%. TREGZI is a personalised treatment manufactured for each patient using living cells from a matched donor.

San Francisco Biotechnology Network
Jun 15th, 2026
Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval.

Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. June 15, 2026 san francisco biotechnology network news news, syndication comments off on orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. Orca Bio, a biotechnology company that works in precision cell therapy, has expanded its Sacramento workforce and added an East Coast manufacturing center in Princeton, New Jersey, as it prepares for commercialization. Click here to view original post

Business Wire
Jun 15th, 2026
Orca Bio expands manufacturing for Orca-T launch with East Coast facility and tripled workforce

Orca Bio has expanded its manufacturing capabilities ahead of the potential launch of its lead cell therapy, Orca-T, adding East Coast manufacturing capacity in Princeton, New Jersey, and tripling its West Coast manufacturing workforce in Sacramento, California. The Princeton facility will serve as a strategic East Coast manufacturing bridge, initially producing therapies for ongoing clinical programmes and supporting commercial production following potential FDA approval. The bicoastal network aims to reduce "vein-to-vein" time for patients nationwide. Orca Bio has more than tripled its Sacramento operations team over the past year, enhancing expertise in manufacturing, supply chain logistics and quality assurance. Orca-T's Biologics License Application is under FDA review, with a target action date of 6 July 2026.